{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:48:22Z","timestamp":1791658102936,"version":"4.3.4"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":250,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.prdoa.2026.100500","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:35:42Z","timestamp":1788968142000},"page":"100500","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Safety of opicapone in the elderly and very elderly population: an analysis of reported events in a global safety database"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6808-0444","authenticated-orcid":false,"given":"Taku","family":"Hatano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"LeWitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier Pagonabarraga","family":"Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno F.","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena C.","family":"Brigas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diogo","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Gama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Holenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prdoa.2026.100500_bb0005","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-080952","article-title":"Projections for prevalence of Parkinson\u2019s disease and its driving factors in 195 countries and territories to 2050: modelling study of global burden of disease study 2021","volume":"388","author":"Su","year":"2025","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.prdoa.2026.100500_bb0010","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/jppr.1683","article-title":"Pharmacological management of Parkinson\u2019s disease in older people","volume":"50","author":"Mouchaileh","year":"2020","journal-title":"J. Pharm. Pract. Res."},{"issue":"S1","key":"10.1016\/j.prdoa.2026.100500_bb0015","doi-asserted-by":"crossref","first-page":"i36","DOI":"10.1093\/ageing\/afy205.04","article-title":"Efficacy and safety of opicapone in patients over 70 years with Parkinson\u2019s disease and motor fluctuations","volume":"48","author":"Lees","year":"2019","journal-title":"Age Ageing"},{"issue":"4","key":"10.1016\/j.prdoa.2026.100500_bb0020","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3233\/JPD-191593","article-title":"Safety profile of Opicapone in the Management of Parkinson\u2019s disease","volume":"9","author":"Lees","year":"2019","journal-title":"J. Parkinsons Dis."},{"issue":"4","key":"10.1016\/j.prdoa.2026.100500_bb0025","doi-asserted-by":"crossref","DOI":"10.47795\/ONNS5189","article-title":"Hallucinations in Parkinson\u2019s disease: new insights into mechanisms and treatments","volume":"19","author":"Weil","year":"2020","journal-title":"Adv. Clin. Neurosci. Rehabil."},{"issue":"9","key":"10.1016\/j.prdoa.2026.100500_bb0030","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s00702-021-02389-x","article-title":"Implications of dopaminergic medication withdrawal in Parkinson\u2019s disease","volume":"129","author":"Koschel","year":"2022","journal-title":"J. Neural Transm."},{"issue":"12","key":"10.1016\/j.prdoa.2026.100500_bb0035","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/mdc3.70249","article-title":"Foslevodopa\/Foscarbidopa continuous subcutaneous infusion in Parkinson\u2019s disease: real-world short-term data on tolerability, infusion rate adjustments and concomitant medication","volume":"12","author":"Rukavina","year":"2025","journal-title":"Mov Disord Clin Pract"},{"issue":"4","key":"10.1016\/j.prdoa.2026.100500_bb0040","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000201565","article-title":"Changes in prevalence and incidence of Parkinson\u2019s disease in Japan during a quarter of a century","volume":"32","author":"Yamawaki","year":"2009","journal-title":"Neuroepidem"},{"issue":"3","key":"10.1016\/j.prdoa.2026.100500_bb0045","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3233\/JPD-191683","article-title":"Parkinson\u2019s disease in women and men: what\u2019s the difference?","volume":"9","author":"Cerri","year":"2019","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.prdoa.2026.100500_bb0050","doi-asserted-by":"crossref","DOI":"10.2174\/011570159X407015250910194113","article-title":"Gender differences in efficacy and tolerability of opicapone in add on of levodopa. A single-center retrospective cohort study","author":"Fazzina","year":"2026","journal-title":"Curr. Neuropharmacol."},{"issue":"3","key":"10.1016\/j.prdoa.2026.100500_bb0055","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00002826-200405000-00006","article-title":"Frequency, reasons, and risk factors of entacapone discontinuation in Parkinson disease","volume":"27","author":"Parashos","year":"2004","journal-title":"Clin. Neuropharmacol."},{"issue":"3","key":"10.1016\/j.prdoa.2026.100500_bb0060","first-page":"263","article-title":"Hepatotoxic profile of catechol-O-methyltransferase inhibitors in Parkinson\u2019s disease","volume":"2","author":"Benabou","year":"2003","journal-title":"Expert Opin. Drug Saf."}],"container-title":["Clinical Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112526000800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112526000800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T17:49:16Z","timestamp":1791654556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590112526000800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":12,"alternative-id":["S2590112526000800"],"URL":"https:\/\/doi.org\/10.1016\/j.prdoa.2026.100500","relation":{},"ISSN":["2590-1125"],"issn-type":[{"value":"2590-1125","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of opicapone in the elderly and very elderly population: an analysis of reported events in a global safety database","name":"articletitle","label":"Article Title"},{"value":"Clinical Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prdoa.2026.100500","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100500"}}